COMPANY PROFILE

Healios

Explore full profile

Our mission is to foster a “Life Explosion” that enriches the lives of people around the world

Tokyo, JapanFounded 2011Biotech & Life Sciences

Valuation $250–500M Last recorded · 2026

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Healios

Healios K.K. is a pioneering biotechnology company specializing in regenerative medicine, focusing on the development and commercialization of treatments using induced pluripotent stem cells (iPSCs). The company serves a global market, targeting serious conditions such as ischemic stroke and age-related macular degeneration. Healios operates through strategic partnerships and licensing agreements with leading institutions like Nikon Corporation, Athersys, Inc., and RIKEN. The business model revolves around research and development, followed by licensing and commercialization of its proprietary cell therapy products. Revenue is generated through product sales, licensing fees, and milestone payments. Healios aims to bring cutting-edge medical solutions to market efficiently, leveraging its robust intellectual property portfolio and strategic alliances. Keywords: regenerative medicine, iPSC technology, cell therapy, ischemic stroke, macular degeneration, biotechnology, licensing agreements, strategic partnerships, commercialization, intellectual property.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2011
Headquarters: Tokyo, Japan
Employees: 32
Open positions: None listed
Dealroom signal: 79.3/100
Industry: Health
Sub-industry: BioTechnology, Health Platform
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Investment activity: 1 company, latest Apr 2024
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
IPO✓Exit	Jun 2015	$0	—	Undisclosed	—
LATE VC✓Equity / VC	Oct 2013	$23M	$92M	Dainippon Sumitomo Pharma · Shin Nippon Biomedical Laboratories (SNBL) · Nikon	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Healios website traffic

Latest recorded traffic for Healios is 22K monthly website visits, up 10% over the last three months. Healios's team grew 10.3% over the past year.

Latest monthly visits22K 3-month web change+10% 1-year team growth+10.3%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
AIAirBiometricsHelps to regain sovereignty over well-being	Castellón de la Plana, Spain	Operational	8	$220K	$880K
LPLuda PartnersThe first pharmaceutical technology platform for pharmacists	Madrid, Spain	Operational
IBInherent BiosciencesA Biotech Startup at the intersection of Epigenetics and AI	Salt Lake City, United States	Operational
COConvexaEnables the rapid creation of voice assistants that autonomously learn, deliver personalized actionable insights, and increase productivity by eliminating manual tasks	Thousand Oaks, United States	Operational
R-R-ZeroThe first biosafety technology company dedicated to making the indoor spaces we share safer, healthier and more productive	Salt Lake City, United States	Operational
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
ACAccexibleDeveloping a speech analysis platform based on AI models to early detect diseases as dementia, Parkinson, and coronary disease	Bilbao, Spain	Operational
VEVETBIOLIXDevelops innovative products for the treatment and prevention of chronic diseases affecting chi	Loos, France	Operational